Magnesium oxide

Identification

Name
Magnesium oxide
Accession Number
DB01377
Type
Small Molecule
Groups
Approved
Description

Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. [PubChem]

Structure
Thumb
Synonyms
  • Magmitt
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Magnesium Citrate Oral SolutionLiquid1.75 gOralD.C. Labs Limited1951-12-312003-07-11Canada
Magnesium OxideTablet400 mg/1OralSafecor Health, LLC2014-09-30Not applicableUs
Magnesium OxideTablet253 mg/1OralQualitest2003-10-06Not applicableUs
Magnesium OxideTablet400 mg/1OralVirtus Pharmaceuticals2015-09-08Not applicableUs
Magnesium OxideTablet400 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Magnesium OxideTablet400 mg/1Oralbryant ranch prepack2015-09-08Not applicableUs
Magnesium OxideTablet400 mg/1OralVirtus Pharmaceuticals2014-04-092016-10-22Us
Magnesium OxideTablet400 mg/1OralQualitest2003-12-03Not applicableUs
Magnesium OxideTablet400 mg/1OralPhysicians Total Care, Inc.2004-07-15Not applicableUs
Magnesium Oxide 420 - CapletTablet250 mgOralHealth Wise Nutrition Inc.1995-12-312002-07-18Canada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Magnesium OxideTablet420 mg/1OralRichmond Pharmaceuticals2016-02-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Active FEMagnesium oxide (30 mg/1) + Beta carotene (2100 [iU]/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (1 mg/1) + Cyanocobalamin (30 ug/1) + Folic Acid (1250 ug/1) + Iron (75 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (4 mg/1) + Thiamine Hydrochloride (4 mg/1) + Vitamin C (160 mg/1) + Vitamin E (40 [iU]/1) + Zinc oxide (20 mg/1)TabletOralGm Pharmaceuticals2013-11-11Not applicableUs
Aspirin Plus Stomach Guard Ext.stgth.capletMagnesium oxide (96.9 mg) + Acetylsalicylic acid (500 mg) + Calcium Carbonate (246.2 mg) + Magnesium carbonate (52.3 mg)TabletOralSterling Winthrop Inc.1994-12-311996-09-10Canada
Aspirin Plus Stomach Guard Extra StrengthMagnesium oxide (96.95 mg) + Acetylsalicylic acid (500 mg) + Calcium Carbonate (246.22 mg) + Magnesium carbonate (52.32 mg)TabletOralBayer Inc Consumer Care1995-12-311998-09-28Canada
Aspirin Plus Stomach Guard TabMagnesium oxide (63 mg) + Acetylsalicylic acid (325 mg) + Calcium Carbonate (160 mg) + Magnesium carbonate (34 mg)TabletOralSterling Winthrop Inc.1994-12-311996-09-10Canada
Aspirin With Stomach GuardMagnesium oxide (63 mg) + Acetylsalicylic acid (325 mg) + Calcium Carbonate (160 mg) + Magnesium carbonate (34 mg)TabletOralBayer Inc Consumer Care1997-10-012012-07-12Canada
Aspirin With Stomach Guard Extra Strength - TabMagnesium oxide (96.9 mg) + Acetylsalicylic acid (500 mg) + Calcium Carbonate (246.2 mg) + Magnesium carbonate (52.3 mg)TabletOralBayer Inc Consumer Care1997-07-072012-07-12Canada
B6 Plus TabMagnesium oxide (50 mg) + Niacin (20 mg) + Potassium Citrate (50 mg) + Pyridoxine hydrochloride (50 mg) + Riboflavin (2.4 mg) + Thiamine (10 mg)TabletOralVita Health Products Inc1979-12-312002-08-01Canada
BacminMagnesium oxide (50 mg/1) + Biotin (150 ug/1) + Chromium Cr-51 chloride (.1 mg/1) + Cupric oxide (3 mg/1) + Cyanocobalamin (50 ug/1) + Flavone (50 mg/1) + Folic Acid (1 mg/1) + Ferrous fumarate (27 mg/1) + Manganese gluconate (5 mg/1) + Nicotinamide (100 mg/1) + Calcium pantothenate (25 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (20 mg/1) + Selenomethionine (50 ug/1) + Thiamine mononitrate (20 mg/1) + Vitamin A acetate (2000 [iU]/1) + Vitamin C (500 mg/1) + Vitamin E acetate (30 [iU]/1) + Zinc oxide (22.5 mg/1)Tablet, coatedOralMarnel Pharmaceuticals, Llc2000-04-01Not applicableUs
C-apnto-B6 Vitamins W Magnesium TabMagnesium oxide (60 mg) + Calcium pantothenate (500 mg) + Pyridoxine (250 mg) + Vitamin C (240 mg)TabletOralMetagenics, Inc.1989-12-311996-10-02Canada
Calcium - Magnesium - Zinc TabMagnesium oxide (133 mg) + Calcium Carbonate (333 mg) + Zinc gluconate (8 mg)TabletOralNutristar Health Products (1987) Inc.1992-12-311996-09-09Canada
Categories
UNII
3A3U0GI71G
CAS number
1309-48-4
Weight
Average: 40.304
Monoisotopic: 39.97995652
Chemical Formula
MgO
InChI Key
CPLXHLVBOLITMK-UHFFFAOYSA-N
InChI
InChI=1S/Mg.O
IUPAC Name
oxomagnesium
SMILES
O=[Mg]

Pharmacology

Indication

Magnesium hydroxide is used as a laxative to relieve occasional constipation (irregularity) and as an antacid to relieve indigestion, sour stomach, and heartburn.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

The term "Milk of Magnesia" was first used to describe a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents. Magnesium supplements have also been shown to reduce platelet aggregation by inhibiting in the influx of calcium, a crucial component of platelet aggregation.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Magnesium oxide.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium oxide.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineMagnesium oxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxyamphetamineMagnesium oxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMagnesium oxide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Magnesium oxide.Experimental, Illicit
AcepromazineMagnesium oxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineMagnesium oxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Magnesium oxide.Approved
AlcuroniumMagnesium oxide may increase the neuromuscular blocking activities of Alcuronium.Experimental
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Magnesium oxide.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium oxide.Approved
AlfacalcidolThe serum concentration of Magnesium oxide can be increased when it is combined with Alfacalcidol.Approved, Nutraceutical
AlimemazineMagnesium oxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolMagnesium oxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Magnesium oxide.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium oxide.Approved
AmphetamineMagnesium oxide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Magnesium oxide.Approved
AndrostenedioneThe bioavailability of Androstenedione can be decreased when combined with Magnesium oxide.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Magnesium oxide.Investigational
anecortave acetateThe bioavailability of anecortave acetate can be decreased when combined with Magnesium oxide.Investigational
AtamestaneThe bioavailability of Atamestane can be decreased when combined with Magnesium oxide.Investigational
AtazanavirMagnesium oxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium oxide.Approved
AtracuriumMagnesium oxide may increase the neuromuscular blocking activities of Atracurium.Experimental, Investigational
Atracurium besylateMagnesium oxide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Magnesium oxide.Approved, Investigational
AzimilideThe risk or severity of adverse effects can be increased when Azimilide is combined with Magnesium oxide.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Magnesium oxide.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium oxide.Approved, Investigational
BencyclaneThe risk or severity of adverse effects can be increased when Bencyclane is combined with Magnesium oxide.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Benidipine is combined with Magnesium oxide.Approved, Investigational
BenzphetamineMagnesium oxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium oxide.Approved, Withdrawn
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Magnesium oxide.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium oxide.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Magnesium oxide.Approved
BL-1020Magnesium oxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium oxide.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Magnesium oxide.Approved
CalcitriolThe serum concentration of Magnesium oxide can be increased when it is combined with Calcitriol.Approved, Nutraceutical
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Magnesium oxide.Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Magnesium oxide.Investigational
CaroverineThe risk or severity of adverse effects can be increased when Caroverine is combined with Magnesium oxide.Experimental
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Magnesium oxide.Approved
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium oxide.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Magnesium oxide.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Magnesium oxide.Withdrawn
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium oxide.Approved, Vet Approved
ChlorphentermineMagnesium oxide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineMagnesium oxide can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineMagnesium oxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlortetracyclineMagnesium oxide can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Magnesium oxide.Approved, Investigational
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Magnesium oxide.Approved, Investigational
CinnarizineThe risk or severity of adverse effects can be increased when Cinnarizine is combined with Magnesium oxide.Approved, Investigational
CinoxacinMagnesium oxide can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
CisatracuriumMagnesium oxide may increase the neuromuscular blocking activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateMagnesium oxide may increase the neuromuscular blocking activities of Cisatracurium besylate.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium oxide.Approved
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Magnesium oxide.Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium oxide.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Magnesium oxide.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Magnesium oxide.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Magnesium oxide.Approved, Investigational, Vet Approved
Cortexolone 17α-propionateThe bioavailability of Cortexolone 17α-propionate can be decreased when combined with Magnesium oxide.Investigational
CorticosteroneThe bioavailability of Corticosterone can be decreased when combined with Magnesium oxide.Experimental
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium oxide.Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium oxide.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium oxide.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium oxide.Approved
DarodipineThe risk or severity of adverse effects can be increased when Darodipine is combined with Magnesium oxide.Experimental
DasatinibMagnesium oxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DecamethoniumMagnesium oxide may increase the neuromuscular blocking activities of Decamethonium.Approved
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium oxide.Approved
DeflazacortThe bioavailability of Deflazacort can be decreased when combined with Magnesium oxide.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Magnesium oxide.Approved
DemeclocyclineMagnesium oxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesonideThe bioavailability of Desonide can be decreased when combined with Magnesium oxide.Approved, Investigational
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Magnesium oxide.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Magnesium oxide.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Magnesium oxide.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Magnesium oxide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Magnesium oxide.Vet Approved
DexmethylphenidateMagnesium oxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineMagnesium oxide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionMagnesium oxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Magnesium oxide.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Magnesium oxide.Approved, Investigational
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Magnesium oxide.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Magnesium oxide.Approved
Dipotassium phosphateThe serum concentration of Dipotassium phosphate can be decreased when it is combined with Magnesium oxide.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium oxide.Approved
Domoic AcidMagnesium oxide may increase the neuromuscular blocking activities of Domoic Acid.Experimental
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Magnesium oxide.Investigational
Doxacurium chlorideMagnesium oxide may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxycyclineMagnesium oxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Magnesium oxide.Approved, Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Magnesium oxide.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Magnesium oxide.Approved
EnoxacinMagnesium oxide can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Magnesium oxide.Approved, Investigational
EquileninThe bioavailability of Equilenin can be decreased when combined with Magnesium oxide.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Magnesium oxide.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium oxide.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Magnesium oxide.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Magnesium oxide.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium oxide.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium oxide.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Fendiline is combined with Magnesium oxide.Withdrawn
Ferric CarboxymaltoseMagnesium oxide can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateMagnesium oxide can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ferric pyrophosphateMagnesium oxide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Magnesium oxide.Approved
FleroxacinMagnesium oxide can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
fluasteroneThe bioavailability of fluasterone can be decreased when combined with Magnesium oxide.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium oxide.Approved
FlumequineMagnesium oxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Magnesium oxide.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium oxide.Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Magnesium oxide.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium oxide.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Magnesium oxide.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Magnesium oxide.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Magnesium oxide.Approved
FluphenazineMagnesium oxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Magnesium oxide.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Magnesium oxide.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium oxide.Approved
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium oxide.Approved
Fluticasone propionateThe bioavailability of Fluticasone propionate can be decreased when combined with Magnesium oxide.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Magnesium oxide.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Magnesium oxide.Approved, Investigational, Withdrawn
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium oxide.Approved
GabapentinMagnesium oxide may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
GallamineMagnesium oxide may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideMagnesium oxide may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GallopamilThe risk or severity of adverse effects can be increased when Gallopamil is combined with Magnesium oxide.Investigational
GarenoxacinMagnesium oxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinMagnesium oxide can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Magnesium oxide.Approved, Investigational
GemifloxacinMagnesium oxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineMagnesium oxide may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GrepafloxacinMagnesium oxide can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational, Withdrawn
HalcinonideThe bioavailability of Halcinonide can be decreased when combined with Magnesium oxide.Approved, Investigational, Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Magnesium oxide.Investigational
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium oxide.Approved, Vet Approved
HydroxyamphetamineMagnesium oxide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium oxide.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide.Approved, Investigational
Iofetamine I-123Magnesium oxide may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IronMagnesium oxide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranMagnesium oxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateMagnesium oxide can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidMagnesium oxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium oxide.Approved
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Magnesium oxide.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium oxide.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Magnesium oxide.Approved, Investigational
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Magnesium oxide.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium oxide.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Magnesium oxide.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium oxide.Approved, Investigational
LevofloxacinMagnesium oxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Magnesium oxide.Approved
LidoflazineThe risk or severity of adverse effects can be increased when Lidoflazine is combined with Magnesium oxide.Experimental
Lipoic AcidMagnesium oxide can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
LisdexamfetamineMagnesium oxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LoteprednolThe bioavailability of Loteprednol can be decreased when combined with Magnesium oxide.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Magnesium oxide.Approved, Investigational
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium oxide.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Manidipine is combined with Magnesium oxide.Approved, Investigational
ME-609The bioavailability of ME-609 can be decreased when combined with Magnesium oxide.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium oxide.Approved
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Magnesium oxide.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Magnesium oxide.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Magnesium oxide.Approved, Investigational
MephedroneMagnesium oxide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineMagnesium oxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium oxide.Approved
MesoridazineMagnesium oxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethamphetamineMagnesium oxide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Magnesium oxide.Approved, Vet Approved
MethotrimeprazineMagnesium oxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethoxyphenamineMagnesium oxide may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
Methylene blueMagnesium oxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethylphenidateMagnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium oxide.Approved, Vet Approved
MetocurineMagnesium oxide may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideMagnesium oxide may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium oxide.Experimental
MibefradilThe risk or severity of adverse effects can be increased when Mibefradil is combined with Magnesium oxide.Investigational, Withdrawn
MidomafetamineMagnesium oxide may decrease the excretion rate of Midomafetamine which could result in a higher serum level.Experimental, Illicit, Investigational
MinocyclineMagnesium oxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Magnesium oxide is combined with Misoprostol.Approved
MivacuriumMagnesium oxide may increase the neuromuscular blocking activities of Mivacurium.Approved
MMDAMagnesium oxide may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MometasoneThe bioavailability of Mometasone can be decreased when combined with Magnesium oxide.Approved, Vet Approved
MoricizineMagnesium oxide can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium oxide.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Magnesium oxide.Investigational
Nalidixic AcidMagnesium oxide can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Magnesium oxide.Investigational
NemonoxacinMagnesium oxide can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NeosaxitoxinMagnesium oxide may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium oxide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium oxide.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium oxide.Experimental
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium oxide.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Niludipine is combined with Magnesium oxide.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium oxide.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Magnesium oxide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium oxide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium oxide.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium oxide.Approved, Investigational
NorfloxacinMagnesium oxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl-estroneThe bioavailability of Oleoyl-estrone can be decreased when combined with Magnesium oxide.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Magnesium oxide.Experimental, Investigational
Oxolinic acidMagnesium oxide can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium oxide.Approved
PancuroniumMagnesium oxide may increase the neuromuscular blocking activities of Pancuronium.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Magnesium oxide.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium oxide.Approved
PazufloxacinMagnesium oxide can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinMagnesium oxide can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Magnesium oxide.Approved
PerazineMagnesium oxide can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Magnesium oxide.Approved, Investigational
PerphenazineMagnesium oxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineMagnesium oxide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
PinaveriumThe risk or severity of adverse effects can be increased when Pinaverium is combined with Magnesium oxide.Approved
PipecuroniumMagnesium oxide may increase the neuromuscular blocking activities of Pipecuronium.Approved
Pipemidic acidMagnesium oxide can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidMagnesium oxide can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Magnesium oxide.Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Magnesium oxide.Approved, Nutraceutical
Prasterone sulfateThe bioavailability of Prasterone sulfate can be decreased when combined with Magnesium oxide.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium oxide.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Magnesium oxide.Approved
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Magnesium oxide.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Magnesium oxide.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Magnesium oxide.Approved, Illicit, Investigational
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Magnesium oxide.Experimental, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium oxide.Withdrawn
ProchlorperazineMagnesium oxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineMagnesium oxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineMagnesium oxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PropericiazineMagnesium oxide can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PropiopromazineMagnesium oxide can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrulifloxacinMagnesium oxide can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineMagnesium oxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
PyrantelMagnesium oxide may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuinidineMagnesium oxide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Magnesium oxide.Approved
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Magnesium oxide.Approved
RapacuroniumMagnesium oxide may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Magnesium oxide.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Magnesium oxide.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Magnesium oxide.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium oxide.Approved, Investigational
RitobegronMagnesium oxide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RocuroniumMagnesium oxide may increase the neuromuscular blocking activities of Rocuronium.Approved
RosoxacinMagnesium oxide can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium oxide.Approved
RufloxacinMagnesium oxide can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Magnesium oxide.Approved
SitafloxacinMagnesium oxide can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateThe serum concentration of Sodium glycerophosphate can be decreased when it is combined with Magnesium oxide.Approved
Sodium phosphateThe serum concentration of Sodium phosphate can be decreased when it is combined with Magnesium oxide.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Magnesium oxide.Approved
SparfloxacinMagnesium oxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SuccinylcholineMagnesium oxide may increase the neuromuscular blocking activities of Succinylcholine.Approved
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium oxide.Approved, Investigational
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Magnesium oxide.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Magnesium oxide.Approved
TemafloxacinMagnesium oxide can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TerodilineThe risk or severity of adverse effects can be increased when Terodiline is combined with Magnesium oxide.Experimental
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Magnesium oxide.Investigational
ThiazinamMagnesium oxide can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineMagnesium oxide can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioproperazineMagnesium oxide can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThioridazineMagnesium oxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Magnesium oxide.Approved, Investigational, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Magnesium oxide.Approved
TolevamerThe risk or severity of adverse effects can be increased when Magnesium oxide is combined with Tolevamer.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Magnesium oxide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Magnesium oxide.Approved, Investigational
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Magnesium oxide.Approved, Vet Approved
TriethylenetetramineMagnesium oxide can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TrifluoperazineMagnesium oxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TriflupromazineMagnesium oxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinMagnesium oxide can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
TubocurarineMagnesium oxide may increase the neuromuscular blocking activities of Tubocurarine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium oxide.Approved, Experimental
UlobetasolThe bioavailability of Ulobetasol can be decreased when combined with Magnesium oxide.Approved
VecuroniumMagnesium oxide may increase the neuromuscular blocking activities of Vecuronium.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium oxide.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Magnesium oxide.Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium oxide.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Magnesium oxide.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium oxide.Approved
Food Interactions
Not Available

References

Synthesis Reference

Jajnya D. Panda, Santosh K. Mahapatra, "Process for the production of magnesium oxide from brine or bittern." U.S. Patent US4370422, issued June, 1921.

US4370422
General References
  1. Kh R, Khullar M, Kashyap M, Pandhi P, Uppal R: Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate induced hypertension in rats. J Hypertens. 2000 Jul;18(7):919-26. [PubMed:10930190]
  2. Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD, Dwyer JH, Shah PK, Kaul S: Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol. 1999 Jul 15;84(2):152-6. [PubMed:10426331]
External Links
Human Metabolome Database
HMDB15458
KEGG Drug
D01167
KEGG Compound
C12567
PubChem Compound
14792
PubChem Substance
46504815
ChemSpider
14108
ChEBI
31794
ChEMBL
CHEMBL1200572
PharmGKB
PA450298
Drugs.com
Drugs.com Drug Page
Wikipedia
Magnesia
ATC Codes
A12CC10 — Magnesium oxideA06AD02 — Magnesium oxideA02AA02 — Magnesium oxide
AHFS Codes
  • 56:12.00 — Cathartics and Laxatives
  • 88:29.00* — Minerals

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentNeed for Bowel Preparation1
2CompletedScreeningHealthy Volunteers1
2CompletedSupportive CareCancer Survivors / Cancer, Breast / Menopausal Hot Flushes1
2CompletedSupportive CareCancer Survivors / Cancer, Breast / Menopausal Hot Flushes / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentPseudoxanthoma Elasticum1
3CompletedTreatmentBowel preparation therapy2
3RecruitingOtherBowel preparation therapy1
4CompletedDiagnosticColonoscopy1
4CompletedDiagnosticHemodynamics / Hyponatremias1
4CompletedTreatmentCathartic Colon1
4CompletedTreatmentColonoscopy1
4CompletedTreatmentFunctional Constipation1
4Not Yet RecruitingDiagnosticBowel Preparation Solutions1
4Unknown StatusTreatmentBowel Preparation Solutions / Endoscopy1
Not AvailableCompletedHealth Services ResearchColorectal Liver Metastases1
Not AvailableRecruitingDiagnosticColonoscopy1
Not AvailableWithdrawnScreeningPatients Undergoing Screening or Surveillance Colonoscopy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral
Kit
Tablet, film coatedOral
CapsuleOral
LiquidOral1.75 g
TabletOral253 mg/1
TabletOral400 mg/1
TabletOral420 mg/1
TabletOral250 mg
TabletOral420 mg
TabletOral410 mg
Powder, for solutionOral
Tablet, coatedOral
Powder, meteredOral
SolutionIrrigation
LiquidIrrigation
Tablet, chewableOral
Capsule, gelatin coatedOral
Capsule, liquid filledOral
Prices
Unit descriptionCostUnit
Phillips 500 mg caplet0.18USD caplet
Magnesium oxide 400 mg tablet0.13USD tablet
Magnesium oxide 420 mg tablet0.11USD tablet
Magox 400 tablet0.11USD tablet
Mag-oxide 400 mg tablet0.09USD tablet
Magnesium oxide powder heavy0.05USD g
Magnesium oxide 500 mg tablet0.04USD tablet
Maox 420 mg tablet0.04USD tablet
Magnesium oxide 250 mg tablet0.03USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8450338No2008-10-102028-10-10Us
US8481083No2008-10-102028-10-10Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-1.1ChemAxon
pKa (Strongest Basic)13.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area17.07 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity1.44 m3·mol-1ChemAxon
Polarizability2.88 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9838
Blood Brain Barrier+0.9837
Caco-2 permeable+0.6708
P-glycoprotein substrateNon-substrate0.8922
P-glycoprotein inhibitor INon-inhibitor0.9725
P-glycoprotein inhibitor IINon-inhibitor0.995
Renal organic cation transporterNon-inhibitor0.9248
CYP450 2C9 substrateNon-substrate0.8638
CYP450 2D6 substrateNon-substrate0.894
CYP450 3A4 substrateNon-substrate0.8026
CYP450 1A2 substrateNon-inhibitor0.8153
CYP450 2C9 inhibitorNon-inhibitor0.9268
CYP450 2D6 inhibitorNon-inhibitor0.9535
CYP450 2C19 inhibitorNon-inhibitor0.9338
CYP450 3A4 inhibitorNon-inhibitor0.9869
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9062
Ames testNon AMES toxic0.7478
CarcinogenicityCarcinogens 0.7198
BiodegradationReady biodegradable0.7705
Rat acute toxicity2.2618 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9031
hERG inhibition (predictor II)Non-inhibitor0.977
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen is an alkaline earth metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal organides
Sub Class
Alkaline earth metal oxides
Direct Parent
Alkaline earth metal oxides
Alternative Parents
Inorganic oxides
Substituents
Alkaline earth metal oxide / Inorganic oxide
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on July 06, 2007 14:30 / Updated on November 22, 2017 12:35